MAB
MABION GPW LISTED

Contracts

All Active Completed

source: current reports (ESPI/EBI) · incomplete data — not every contract is disclosed · 6 contracts in the database

DISCLOSED VALUE 12M
145 k USD
1 of 4 contracts
SHARE OF REVENUE 12M
currency other than PLN
LARGEST COUNTERPARTY
100%
Novavax, Inc.
LONGEST TERM
4 years
until 2029
Fulfilled

WPD Pharmaceuticals Sp. z o.o.

undisclosed

Realizacja/Odbiór · Rozwój metod analitycznych dla kandydata na lek w postaci białka rekombinowanego skoniugowanego z substancją cytotoksyczną oraz białkowego półproduktu

Rozwój metod analitycznych dla kandydata na lek w postaci białka rekombinowanego skoniugowanego z substancją cytotoksyczną oraz białkowego półproduktu

Status

Fulfilled

Signing date

Term

Report H1 2026

SHOWING 1–1 OF 1

Portfolio summary

Contracts
6
Active
5
Total value
145 k USD
Average value
145 k USD
Since
May 07, 2026

Where this data comes from

Contracts come from current reports (ESPI/EBI) — the company discloses only those exceeding its materiality threshold. The list is by definition incomplete.

Status — inferred from the event type and the term's end date, not a dedicated source field.

Share of revenue 12M — only when both the contracts' dominant currency and the company's reporting currency are PLN, with no currency conversion.